Skip to main content
. 2019 Dec 26;47(3):665–673. doi: 10.1007/s00259-019-04635-7

Fig. 3.

Fig. 3

SUVmax trend in parotid glands (a), liver (b), submandibular glands (c), spleen (d), sublingual glands (e), and kidneys (f) after initiation of ADT (degarelix): blue lines, lesions with decreasing SUVmax; red lines, lesions with increasing SUVmax trend compared with baseline; dotted vertical line, initiation of androgen deprivation therapy (ADT)